7 Multiple Sclerosis Headlines

0
(0)

5 – MS Relapses During Natalizumab Therapy Traced to Drug’s Greater Impact on Regulatory T-cells

news_11_Artboard 343 copy 67

Natalizumab (Tysabri) harnesses multiple sclerosis (MS) activity by targeting CD49, a molecule on the surface of immune cells. Now, researchers found that the drug reduces the factor on regulatory T-cells to a greater extent than on inflammatory T-cells — a mechanism that might explain disease exacerbation during treatment.

Read full article here: http://bit.ly/1VRIhbE

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *